A PYMNTS Company

EU: Novartis Recommended For EU Approval

By  |  March 11, 2015

Zykadia from Novartis was recommended for EU approval to address treatment for adult patients suffering from anapestic lymphoma kinase -positive advanced non-small cell lung cancer also known as ALK+NSCLC, which has been treated previously with crizotinib.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    If approved, this would be the first treatment option for patients in Europe.

     

    Full Content: Mondaq

     

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.